A four-arm, randomized, double-blind, parallel, placebo-controlled exploratory study of pagoclone 0.15mg, 0.30mg, and 0.60mg in men with primary premature ejaculation.

Trial Profile

A four-arm, randomized, double-blind, parallel, placebo-controlled exploratory study of pagoclone 0.15mg, 0.30mg, and 0.60mg in men with primary premature ejaculation.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2012

At a glance

  • Drugs Pagoclone (Primary)
  • Indications Premature ejaculation
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2012 Actual end date changed from Sep 2006 to Oct 2006 as reported by ClinicalTrials.gov.
    • 13 Feb 2007 Status change from discontinued
    • 17 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top